MedTrace Logo

SD vs. NSD Therapy in Elderly AML

NCT03733834 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2018-11-07

No results posted yet for this study

Summary

It is known that treatment outcome could be positively associated with treatment intensity. However, tolerance of chemotherapy decreases in the elder, some patients could not tolerate standard (SD) therapy and even died of side effect, and overall survival (OS) might not be prolonged. Whether all elder acute myeloid leukemia (AML) patients could benefit from SD therapy, or some should receive reduced-intensity therapy or even only supporting care remains controvertal. In this multi-center study, we are going to evaluate the benefit of SD and non-SD (NSD) therapy in elder AML patients.

Conditions

  • Standard Therapy
  • Non-standard Therapy

Sponsors & Collaborators

  • Second Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Guangzhou First People's Hospital

    collaborator OTHER

  • Shenzhen Hospital of Southern Medical University

    collaborator OTHER

  • Wuhan General Hospital of Guangzhou Military Command

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • First Affiliated Hospital of Shenzhen University

    collaborator UNKNOWN

  • Zhongshan People's Hospital, Guangdong, China

    collaborator OTHER

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • Xiangya Hospital of Zhongnan University

    collaborator UNKNOWN

  • The Third Xiangya Hospital of Central South University

    collaborator OTHER

  • First Affiliated Hospital of Gannan Medical University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Qifa Liu · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
60 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-08
Primary Completion
2020-09-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03733834 on ClinicalTrials.gov